S&P 500   3,783.57 (-0.19%)
DOW   30,298.87 (-0.06%)
QQQ   280.65 (-0.52%)
AAPL   145.59 (-0.35%)
MSFT   247.89 (-0.40%)
META   137.75 (-1.80%)
GOOGL   100.72 (-0.91%)
AMZN   120.08 (-0.83%)
TSLA   237.98 (-4.59%)
NVDA   130.56 (-0.84%)
NIO   15.88 (-5.08%)
BABA   84.19 (+0.10%)
AMD   67.34 (-0.82%)
T   15.94 (-0.93%)
MU   54.39 (+0.80%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.59 (+0.07%)
DIS   99.77 (-1.65%)
AMC   7.26 (-7.28%)
PYPL   93.38 (+0.64%)
PFE   44.08 (-0.85%)
NFLX   233.96 (-2.82%)
S&P 500   3,783.57 (-0.19%)
DOW   30,298.87 (-0.06%)
QQQ   280.65 (-0.52%)
AAPL   145.59 (-0.35%)
MSFT   247.89 (-0.40%)
META   137.75 (-1.80%)
GOOGL   100.72 (-0.91%)
AMZN   120.08 (-0.83%)
TSLA   237.98 (-4.59%)
NVDA   130.56 (-0.84%)
NIO   15.88 (-5.08%)
BABA   84.19 (+0.10%)
AMD   67.34 (-0.82%)
T   15.94 (-0.93%)
MU   54.39 (+0.80%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.59 (+0.07%)
DIS   99.77 (-1.65%)
AMC   7.26 (-7.28%)
PYPL   93.38 (+0.64%)
PFE   44.08 (-0.85%)
NFLX   233.96 (-2.82%)
S&P 500   3,783.57 (-0.19%)
DOW   30,298.87 (-0.06%)
QQQ   280.65 (-0.52%)
AAPL   145.59 (-0.35%)
MSFT   247.89 (-0.40%)
META   137.75 (-1.80%)
GOOGL   100.72 (-0.91%)
AMZN   120.08 (-0.83%)
TSLA   237.98 (-4.59%)
NVDA   130.56 (-0.84%)
NIO   15.88 (-5.08%)
BABA   84.19 (+0.10%)
AMD   67.34 (-0.82%)
T   15.94 (-0.93%)
MU   54.39 (+0.80%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.59 (+0.07%)
DIS   99.77 (-1.65%)
AMC   7.26 (-7.28%)
PYPL   93.38 (+0.64%)
PFE   44.08 (-0.85%)
NFLX   233.96 (-2.82%)
S&P 500   3,783.57 (-0.19%)
DOW   30,298.87 (-0.06%)
QQQ   280.65 (-0.52%)
AAPL   145.59 (-0.35%)
MSFT   247.89 (-0.40%)
META   137.75 (-1.80%)
GOOGL   100.72 (-0.91%)
AMZN   120.08 (-0.83%)
TSLA   237.98 (-4.59%)
NVDA   130.56 (-0.84%)
NIO   15.88 (-5.08%)
BABA   84.19 (+0.10%)
AMD   67.34 (-0.82%)
T   15.94 (-0.93%)
MU   54.39 (+0.80%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.59 (+0.07%)
DIS   99.77 (-1.65%)
AMC   7.26 (-7.28%)
PYPL   93.38 (+0.64%)
PFE   44.08 (-0.85%)
NFLX   233.96 (-2.82%)
NYSEAMERICAN:STXS

Stereotaxis - STXS Stock Forecast, Price & News

$1.88
0.00 (0.00%)
(As of 10/5/2022 01:16 PM ET)
Add
Compare
Today's Range
$1.85
$1.88
50-Day Range
N/A
52-Week Range
$1.72
$7.22
Volume
491 shs
Average Volume
165,192 shs
Market Capitalization
$140.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.40

Stereotaxis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
346.8% Upside
$8.40 Price Target
Short Interest
Bearish
2.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.90mentions of Stereotaxis in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.24) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

STXS stock logo

About Stereotaxis (NYSEAMERICAN:STXS) Stock

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

STXS Stock News Headlines

Stereotaxis (NYSEMKT: STXS)
Stereotaxis (STXS) Q2 2022 Earnings Call Transcript
Recap: Stereotaxis Q2 Earnings - Benzinga
See More Headlines
Receive STXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter.

STXS Company Calendar

Last Earnings
8/09/2022
Today
10/05/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:STXS
CIK
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.40
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+346.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-10,720,000.00
Pretax Margin
-56.30%

Debt

Sales & Book Value

Annual Sales
$35.02 million
Book Value
$0.45 per share

Miscellaneous

Free Float
60,460,000
Market Cap
$140.61 million
Optionable
Optionable
Beta
1.68

Key Executives

  • Dr. David Leo Fischel C.A.I.A. (Age 35)
    C.F.A., C.P.A., M.B.A., CFA, CPA, CEO & Chairman
    Comp: $62.2k
  • Ms. Kimberly R. Peery
    CFO & Sec.
  • Mr. Keith Galloway
    VP of Operations
  • Ms. Laura Spencer Garth
    Gen. Counsel
  • John Platt
    Sr. Director of Project Management & Systems Software
  • Nathan Kastelein
    R&D Leader and Sr. Director of R&D and Advanced Concepts
  • Brian Kidd
    R&D Leader and Sr. Director of Product Devel.
  • Mr. Guy Judkowski
    Equity Portfolio Mang.













STXS Stock - Frequently Asked Questions

Should I buy or sell Stereotaxis stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STXS shares.
View STXS analyst ratings
or view top-rated stocks.

What is Stereotaxis' stock price forecast for 2022?

4 analysts have issued twelve-month price objectives for Stereotaxis' stock. Their STXS share price forecasts range from $6.00 to $13.00. On average, they predict the company's stock price to reach $8.40 in the next year. This suggests a possible upside of 346.8% from the stock's current price.
View analysts price targets for STXS
or view top-rated stocks among Wall Street analysts.

How have STXS shares performed in 2022?

Stereotaxis' stock was trading at $5.51 at the beginning of 2022. Since then, STXS shares have decreased by 65.9% and is now trading at $1.88.
View the best growth stocks for 2022 here
.

When is Stereotaxis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our STXS earnings forecast
.

How were Stereotaxis' earnings last quarter?

Stereotaxis, Inc. (NYSEAMERICAN:STXS) issued its earnings results on Tuesday, August, 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The firm earned $6.15 million during the quarter, compared to analyst estimates of $7.60 million. Stereotaxis had a negative trailing twelve-month return on equity of 52.64% and a negative net margin of 56.30%.

What is Stereotaxis' stock symbol?

Stereotaxis trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "STXS."

How do I buy shares of Stereotaxis?

Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Stereotaxis' stock price today?

One share of STXS stock can currently be purchased for approximately $1.88.

How much money does Stereotaxis make?

Stereotaxis (NYSEAMERICAN:STXS) has a market capitalization of $140.61 million and generates $35.02 million in revenue each year. The company earns $-10,720,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis.

How many employees does Stereotaxis have?

The company employs 130 workers across the globe.

How can I contact Stereotaxis?

Stereotaxis' mailing address is 4320 FOREST PARK AVENUE SUITE 100, ST.LOUIS MO, 63108. The official website for the company is www.stereotaxis.com. The company can be reached via phone at (314) 678-6100, via email at investors@stereotaxis.com, or via fax at 314-678-6159.

This page (NYSEAMERICAN:STXS) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.